OTLKOutlook Therapeutics, Inc.同业对比
Outlook Therapeutics, Inc. 与SIC 2836 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OTLK本股 | $166M#8 | — | — | 117.4x#11 | — | 17.2%#5 | -4744.3%#10 | — | -12.8%#1 | — | -33.8%#7 | — |
| ALEC | $206M#1 | — | — | 9.8x#6 | -79.1%#6 | -20.2%#9 | -741.3%#7 | — | — | — | — | — |
| SRZN | $200M#2 | — | — | 57.6x#9 | -67.4%#5 | -280.8%#14 | -1210.6%#8 | — | — | — | 43.9%#1 | — |
| CHRS | $190M#4 | — | 3.1x#7 | 4.5x#2 | 59.8%#1 | 489.4%#1 | -429.5%#5 | 276.2%#3 | -351.2%#2 | — | -9.2%#5 | — |
| ACOG | $193M#3 | — | 3.6x#10 | 18.9x#8 | — | -39.8%#10 | -221.7%#3 | -39.0%#5 | — | — | 6.1%#4 | — |
| VYGR | $186M#5 | — | 1.2x#4 | 4.6x#3 | -49.5%#3 | -84.2%#12 | -326.6%#4 | -77.6%#7 | — | — | -29.2%#6 | — |
| ABOS | $184M#6 | — | 3.2x#8 | — | — | -18.6%#8 | — | -211.9%#12 | -421.4%#3 | — | — | — |
| DTIL | $177M#7 | — | 3.9x#11 | 5.2x#4 | -50.1%#4 | -738.0%#15 | -152.2%#2 | -101.0%#8 | — | — | 41.0%#3 | — |
| HUMA | $159M#9 | — | 5.1x#12 | 78.0x#10 | — | 72.5%#3 | -5306.0%#11 | -130.6%#10 | — | — | — | — |
| ARMP | $155M#10 | — | — | — | — | -818.8%#16 | — | — | — | — | 41.5%#2 | 0.1%#1 |
| TNYA | $152M#11 | — | 2.2x#6 | — | — | 18.5%#4 | — | -130.5%#9 | — | — | — | — |
| NMRA | $144M#12 | — | 3.2x#9 | — | — | -2.8%#7 | — | 532.2%#2 | -594.0%#4 | — | -46.5%#8 | — |
| CRBU | $141M#13 | — | 1.4x#5 | 12.6x#7 | 11.7%#2 | 0.7%#6 | -1329.4%#9 | -151.0%#11 | — | — | — | — |
| LENZ | $126M#15 | — | 0.6x#2 | 6.6x#5 | — | -65.0%#11 | -477.5%#6 | -37.5%#4 | — | — | -90.5%#9 | — |
| ENGN | $127M#14 | 0.8x#1 | 0.6x#1 | — | — | -112.7%#13 | — | -50.9%#6 | — | — | — | — |
| BDTX | $112M#16 | — | 1.2x#3 | 1.6x#1 | — | 132.1%#2 | 17.9%#1 | 23276.9%#1 | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议